Prevention of cardiovascular ischemic events: High-risk and secondary preventionGENEST, Jacques; PEDERSEN, Terje R.Circulation (New York, N.Y.). 2003, Vol 107, Num 15, pp 2059-2065, issn 0009-7322, 7 p.Article

Identification of a novel human cellular HDL biosynthesis defectRASHID, Shirya; MARCIL, Michel; RUEL, Isabelle et al.European heart journal. 2009, Vol 30, Num 18, pp 2204-2212, issn 0195-668X, 9 p.Article

Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery diseaseMIKAEL, Leonie G; GENEST, Jacques; ROZEN, Rima et al.Circulation research. 2006, Vol 98, Num 4, pp 564-571, issn 0009-7330, 8 p.Article

Homocysteine and cardiovascular disease in diabetes mellitusAUDELIN, Marie Chantal; GENEST, Jacques JR.Atherosclerosis. 2001, Vol 159, Num 2, pp 497-511, issn 0021-9150Article

High-density lipoproteins and endothelial functionO'CONNELL, Brian J; GENEST, Jacques JR.Circulation (New York, N.Y.). 2001, Vol 104, Num 16, pp 1978-1983, issn 0009-7322Article

Effect of Fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 Diabetes mellitusGENEST, Jacques; FROHLICH, Jiri; STEINER, George et al.The American journal of cardiology. 2004, Vol 93, Num 7, pp 848-853, issn 0002-9149, 6 p.Article

The nested case-control study in cardiologyESSEBAG, Vidal; GENEST, Jacques JR; SUISSA, Samy et al.The American heart journal. 2003, Vol 146, Num 4, pp 581-590, issn 0002-8703, 10 p.Article

Aortic calcification: Novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptorFANTUS, Daniel; AWAN, Zuhier; SEIDAH, Nabil G et al.Atherosclerosis. 2013, Vol 226, Num 1, pp 9-15, issn 0021-9150, 7 p.Article

Functional mutations of the ABCA1 gene in subjects of French-Canadian descent with HDL deficiencyALRASADI, Khalid; RUEL, Isabelle L; MARCIL, Michel et al.Atherosclerosis. 2006, Vol 188, Num 2, pp 281-291, issn 0021-9150, 11 p.Article

Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease : The women's Atorvastatin Trial on Cholesterol (WATCH)MCPHERSON, Ruth; ANGUS, Carmella; MURRAY, Peter et al.The American heart journal. 2001, Vol 141, Num 6, pp 949-956, issn 0002-8703Article

Cellular phospholipid and cholesterol efflux in high-density lipoprotein deficiencyMARCIL, Michel; BISSONNETTE, Rachel; VINCENT, Jérome et al.Circulation (New York, N.Y.). 2003, Vol 107, Num 10, pp 1366-1371, issn 0009-7322, 6 p.Article

The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor AgonistsFRIEDLAND, Sayuri N; LEONG, Aaron; FILION, Kristian B et al.The American journal of medicine. 2012, Vol 125, Num 2, pp 126-133, issn 0002-9343, 8 p.Article

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin : a prospective study of the J U PITER trialRIDKER, Paul M; DANIELSON, Eleanor; NORDESTGAARD, Børge G et al.Lancet (British edition). 2009, Vol 373, Num 9670, pp 1175-1182, issn 0140-6736, 8 p.Article

Stress Pathways to Spontaneous Preterm Birth: The Role of Stressors, Psychological Distress, and Stress HormonesKRAMER, Michael S; LYDON, John; MEANEY, Michael J et al.American journal of epidemiology. 2009, Vol 169, Num 11, pp 1319-1326, issn 0002-9262, 8 p.Article

Genetic and Pharmacological Manipulation of Urotensin II Ameliorate the Metabolic and Atherosclerosis Sequalae in MiceZHIPENG YOU; GENEST, Jacques; BARRETTE, Pierre-Olivier et al.Arteriosclerosis, thrombosis, and vascular biology. 2012, Vol 32, Num 8, pp 1809-1816, issn 1079-5642, 8 p.Article

RVX-208: A Small Molecule That Increases Apolipoprotein A-I and High-Density Lipoprotein Cholesterol In Vitro and In VivoBAILEY, Dana; JAHAGIRDAR, Ravi; KRIMBOU, Larbi et al.Journal of the American College of Cardiology. 2010, Vol 55, Num 23, pp 2580-2589, issn 0735-1097, 10 p.Article

Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk: Implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for Intermediate RiskRIDKER, Paul M; MACFADYEN, Jean G; NORDESTGAARD, Børge G et al.Circulation. Cardiovascular quality and outcomes (Print). 2010, Vol 3, Num 5, pp 447-452, issn 1941-7713, 6 p.Article

Subclinical inflammation and prothrombotic state in heart transplant recipients : Impact of cyclosporin microemulsion vs. tacrolimusWHITE, Michel; ROSS, Heather; BURTON, Jeffrey et al.Transplantation. 2006, Vol 82, Num 6, pp 763-770, issn 0041-1337, 8 p.Article

Urotensin II differentially regulates macrophage and hepatic cholesterol homeostasisKISS, Robert S; ZHIPENG YOU; GENEST, Jacques et al.Peptides (New York, NY. 1980). 2011, Vol 32, Num 5, pp 956-963, issn 0196-9781, 8 p.Article

Fine mapping and association studies of a high-density lipoprotein cholesterol linkage region on chromosome 16 in French-Canadian subjectsDASTANI, Zari; PAJUKANTA, Päivi; RIOUX, John et al.European journal of human genetics. 2010, Vol 18, Num 3, pp 342-347, issn 1018-4813, 6 p.Article

Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive ProteinRIDKER, Paul M; FONSECA, Francisco A. H; SHEPHERD, James et al.The American journal of cardiology. 2007, Vol 100, Num 11, pp 1659-1664, issn 0002-9149, 6 p.Article

Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine /atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)HOBBS, F. D. Richard; GENSINI, Gianfranco; METCALFE, Michael et al.International journal of cardiology. 2006, Vol 110, Num 2, pp 242-250, issn 0167-5273, 9 p.Article

Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia : The Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsionWHITE, Michel; HADDAD, Haissam; HOWLETT, Jonathan et al.The Journal of heart and lung transplantation. 2005, Vol 24, Num 7, pp 798-809, issn 1053-2498, 12 p.Article

Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart diseaseDORVAL, Jean-Francois; ANDERSON, Todd; WALLING, Ann et al.The American journal of cardiology. 2005, Vol 95, Num 2, pp 249-253, issn 0002-9149, 5 p.Article

Calcium and Vitamin D Intake and Mortality: Results from the Canadian Multicentre Osteoporosis Study (CaMos)LANGSETMO, Lisa; BERGER, Claudie; PRIOR, Jerilynn C et al.The Journal of clinical endocrinology and metabolism. 2013, Vol 98, Num 7, pp 3010-3018, issn 0021-972X, 9 p.Article